Home › Cardiovascular Disease › NCT05945121

Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

Cardio-Oncology Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult 18 years or older
* Referred for HSCT evaluation
* Presence of least one CV risk factor at enrollment (hypertension, hyperlipidemia, atrial fibrillation, obesity, heart failure, history of coronary artery disease, diabetes)
* Able to ambulate unassisted
* Ability to understand and the willingness to sign a written informed consent
* Ability to use Polar Flow heart rate application

Exclusion Criteria:

* Severe anemia (hemoglobin \<7 gm/dl)
* Untreated high-risk coronary artery disease (left main, triple vessel disease)
* Severe aortic stenosis
* Recent fracture as assessed via self-report
* Gross balance deficits
* Severe pain with basic movement
* Unable to ambulate unassisted or exercise
* NYHA class IV heart failure
* Adults unable to give consent, pregnant women, and prisoners are excluded from this study.

About the study

To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.

What is being tested

• Cardio-oncology program (other)

Sponsor: University of Michigan Rogel Cancer Center · Participants: 10 · Started: Aug 25, 2023

Contact the study team

• Cancer AnswerLine · Phone: 1-800-865-1125

Official record on ClinicalTrials.gov — NCT05945121

Locations in the U.S.

Conditions

• Cardiovascular Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.